Breakthrough Trichosporonosis in Patients with Hematologic Malignancies Receiving Micafungin
Open Access
- 15 March 2006
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (6) , 753-757
- https://doi.org/10.1086/500323
Abstract
Background. Micafungin is a newly approved antifungal agent in the echinocandin class that is active against Candida species and Aspergillus species. However, this agent has limited activity against a number of fungi, including Trichosporon species. We describe 4 patients who developed disseminated trichosporonosis during the use of micafungin. No cases of trichosporonosis had been seen in the 2 years prior to January 2003, when micafungin became available in our hospital. Methods. We reviewed microbiological records of patients at Kameda General Hospital (Kamogawa City, Chiba, Japan) from 1 January 2002 to 31 July 2005, and identified 4 patients whose blood culture results were positive for Trichosporon species. Results. Since January 2003, four patients—3 with acute myelocytic leukemia and 1 with myelodysplastic syndrome—developed disseminated trichosporonosis while receiving treatment with micafungin with or without amphotericin B. The initial 2 isolates were identified as Trichosporon beigelii, and the later 2 isolates were identified as Trichosporon asahii. All 4 patients received micafungin, and 2 also received amphotericin B concomitantly. Minimal inhibitory concentrations of micafungin were >16 µg/mL for the 2 isolates available for susceptibility testing. One patient with hematologic recovery (neutrophils >500 cells/mm3) showed elimination of the fungus after receiving treatment with voriconazole. However, the 3 other patients without hematologic or immunological recovery died of disseminated infection. Conclusions. The rarity of trichosporonosis in our hospital and its emergence after the introduction of micafungin therapy support the idea that micafungin may exert a significant, selective pressure toward resistant fungi, such as Trichosporon species. Therefore, care should be taken regarding the possibility of trichosporonosis in patients receiving micafungin with or without amphotericin B.Keywords
This publication has 20 references indexed in Scilit:
- Invasive Infections Caused byTrichosporonSpecies andGeotrichum capitatumin Patients with Hematological Malignancies: a Retrospective Multicenter Study from Italy and Review of the LiteratureJournal of Clinical Microbiology, 2005
- Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyondCandida albicansandAspergillus fumigatusJournal of Clinical Microbiology, 2004
- Trichosporonosis in a tertiary care cancer center: Risk factors, changing spectrum and determinants of outcomeScandinavian Journal of Infectious Diseases, 2004
- Breakthrough Trichosporonosis in a Bone Marrow Transplant Recipient Receiving Caspofungin AcetateClinical Infectious Diseases, 2002
- Sequence Analysis of the Ribosomal DNA Intergenic Spacer 1 Regions of Trichosporon SpeciesJournal of Clinical Microbiology, 2002
- Trichosporon beigelii: a life-threatening pathogen in immunocompromised hostsBone Marrow Transplantation, 2000
- In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important FungiAntimicrobial Agents and Chemotherapy, 2000
- Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazolSupportive Care in Cancer, 1999
- Trichosporon beigelii Pneumonia in Patients With Hematologic MalignanciesChest, 1995
- Trichosporonosis in Patients with Neoplastic DiseaseMedicine, 1986